Approval · Notice of Compliance 25874 · 2021
HULIO: Notice of Compliance 25874
Issued May 14, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25874
- Date
- May 14, 2021
- Company
- BGP Pharma ULCEtobicoke, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Changes to the drug substance and drug product manufacturing processes and addition of an alternate drug substance manufacturing site
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| HULIO | Not yet assigned | — |
Medicinal ingredients
- ADALIMUMAB 20 MG per SYR
- ADALIMUMAB 40 MG per SYR
- ADALIMUMAB 40 MG per PEN